{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:34:46Z","timestamp":1791063286397,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,9]]},"DOI":"10.7759\/cureus.27824","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T17:19:39Z","timestamp":1660065579000},"source":"Crossref","is-referenced-by-count":6,"title":["Seronegative Immune-Mediated Necrotizing Myopathy: A Case Report"],"prefix":"10.7759","author":[{"given":"Shriya","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abu-Abaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feryal","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-018-0732-6","article-title":"Immune-mediated necrotizing myopathy","volume":"20","author":"Pinal-Fernandez I","year":"2018","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018, 20:21. 10.1007\/s11926-018-0732-6","journal-title":"Curr Rheumatol Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-13-103","article-title":"Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis","volume":"13","author":"Smoyer-Tomic KE","year":"2012","unstructured":"Smoyer-Tomic KE, Amato AA, Fernandes AW. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculoskelet Disord. 2012, 13:103. 10.1186\/1471-2474-13-103","journal-title":"BMC Musculoskelet Disord"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0277-y","article-title":"Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients","volume":"10","author":"Suzuki S","year":"2015","unstructured":"Suzuki S, Nishikawa A, Kuwana M, et al.. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis. 2015, 10:61. 10.1186\/s13023-015-0277-y","journal-title":"Orphanet J Rare Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22920","article-title":"Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle","volume":"69","author":"Pinal-Fernandez I","year":"2017","unstructured":"Pinal-Fernandez I, Parks C, Werner JL, et al.. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res (Hoboken). 2017, 69:263-270. 10.1002\/acr.22920","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew470","article-title":"More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou E","year":"2017","unstructured":"Tiniakou E, Pinal-Fernandez I, Lloyd TE, et al.. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology (Oxford). 2017, 56:787-794. 10.1093\/rheumatology\/kew470","journal-title":"Rheumatology (Oxford)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Grable-Esposito P","year":"2010","unstructured":"Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. 2010, 41:185-190. 10.1002\/mus.21486","journal-title":"Muscle Nerve"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.50.3.764","article-title":"Paraneoplastic necrotizing myopathy: clinical and pathological features","volume":"50","author":"Levin MI","year":"1998","unstructured":"Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology. 1998, 50:764-767. 10.1212\/wnl.50.3.764","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach Y","year":"2016","unstructured":"Allenbach Y, Keraen J, Bouvier AM, et al.. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain. 2016, 139:2131-2135. 10.1093\/brain\/aww054","journal-title":"Brain"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex413","article-title":"Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis","volume":"57","author":"Pinal-Fernandez I","year":"2018","unstructured":"Pinal-Fernandez I, Ferrer-Fabregas B, Trallero-Araguas E, et al.. Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. Rheumatology (Oxford). 2018, 57:388-396. 10.1093\/rheumatology\/kex413","journal-title":"Rheumatology (Oxford)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s E","year":"2012","unstructured":"Trallero-Aragu\u00e1s E, Rodrigo-Pend\u00e1s J\u00c1, Selva-O'Callaghan A, et al.. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012, 64:523-532. 10.1002\/art.33379","journal-title":"Arthritis Rheum"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac144","article-title":"Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation","author":"Shelly S","year":"2022","unstructured":"Shelly S, Beecher G, Milone M, et al.. Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation. Rheumatology (Oxford). 2022, 10.1093\/rheumatology\/keac144","journal-title":"Rheumatology (Oxford)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210198","article-title":"Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity","volume":"76","author":"Pinal-Fernandez I","year":"2017","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, et al.. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis. 2017, 76:681-687. 10.1136\/annrheumdis-2016-210198","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102993","article-title":"Immune-mediated necrotizing myopathy (IMNM): a myopathological challenge","volume":"21","author":"Merlonghi G","year":"2022","unstructured":"Merlonghi G, Antonini G, Garibaldi M. Immune-mediated necrotizing myopathy (IMNM): a myopathological challenge. Autoimmun Rev. 2022, 21:102993. 10.1016\/j.autrev.2021.102993","journal-title":"Autoimmun Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.1082908","article-title":"Treatment of inflammatory myopathy: emerging therapies and therapeutic targets","volume":"11","author":"Moghadam-Kia S","year":"2015","unstructured":"Moghadam-Kia S, Aggarwal R, Oddis CV. Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert Rev Clin Immunol. 2015, 11:1265-1275. 10.1586\/1744666X.2015.1082908","journal-title":"Expert Rev Clin Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X11415306","article-title":"Diagnosis and treatment of the idiopathic inflammatory myopathies","volume":"3","author":"Gazeley DJ","year":"2011","unstructured":"Gazeley DJ, Cronin ME. Diagnosis and treatment of the idiopathic inflammatory myopathies. Ther Adv Musculoskelet Dis. 2011, 3:315-324. 10.1177\/1759720X11415306","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen AL","year":"2015","unstructured":"Mammen AL, Tiniakou E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med. 2015, 373:1680-1682. 10.1056\/NEJMc1506163","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7827","article-title":"Autoantibody-negative immune-mediated necrotizing myopathy responds to early and aggressive treatment: a case report","volume":"12","author":"Marotta DA","year":"2020","unstructured":"Marotta DA, Zadourian A, Jabaay MJ, Kesserwani A, Kesserwani H. Autoantibody-negative immune-mediated necrotizing myopathy responds to early and aggressive treatment: a case report. Cureus. 2020, 12:e7827. 10.7759\/cureus.7827","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180308","article-title":"Current classification and management of inflammatory myopathies","volume":"5","author":"Schmidt J","year":"2018","unstructured":"Schmidt J. Current classification and management of inflammatory myopathies. J Neuromuscul Dis. 2018, 5:109-129. 10.3233\/JND-180308","journal-title":"J Neuromuscul Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/103329-seronegative-immune-mediated-necrotizing-myopathy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:57Z","timestamp":1707507417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/103329-seronegative-immune-mediated-necrotizing-myopathy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.27824","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,9]]}}}